Summary
Edwards Lifesciences Corporation's (EW) third-quarter 2003 filing shows a significant rebound in financial performance compared to the prior year. For the nine months ended September 30, 2003, the company reported net income of $60.1 million, a substantial increase from $34.0 million in the same period of 2002. This growth was driven by a 27.1% increase in net sales, reaching $636.4 million, fueled by strong performance in Cardiac Surgery and Critical Care segments, alongside a favorable impact from accounting changes related to the Japan business and currency exchange rates. The company also managed its expenses effectively, with gross profit margins remaining strong at 58.3% for the nine-month period. While SG&A expenses increased as a percentage of sales due to consolidation of the Japan business, R&D expenses as a percentage of sales decreased, indicating improved operational efficiency. The balance sheet shows an increase in total assets to $1,070.8 million from $1,008.2 million at year-end 2002. Notably, the company raised significant capital through the issuance of $150 million in convertible senior debentures, bolstering its liquidity.
Key Highlights
- 1Net sales increased by 24.3% to $206.1 million for the three months ended September 30, 2003, and by 27.1% to $636.4 million for the nine months ended September 30, 2003, compared to the prior year periods.
- 2Net income for the nine months ended September 30, 2003, was $60.1 million, a significant improvement from $34.0 million in the same period of 2002.
- 3Gross profit margin remained strong at 57.8% for the three months and 58.3% for the nine months ended September 30, 2003.
- 4The company raised $150 million in proceeds from the issuance of convertible senior debentures in May 2003, strengthening its cash position.
- 5Special charges included a $13.0 million severance charge in the third quarter of 2003 for workforce streamlining and $11.8 million in purchased in-process R&D expenses related to the Jomed N.V. acquisition.
- 6Significant legal proceedings are ongoing, including patent infringement lawsuits against St. Jude Medical, Inc. and Medtronic/Cook/Gore, though management believes these will not materially adversely affect the company's financial position.
- 7The company completed the sale of its German perfusion services subsidiary effective July 4, 2003.